Mức độ cytokine và mối quan hệ của chúng với tình trạng ký sinh trùng và bệnh cơ tim ở những người mắc bệnh Chagas tại Tây Ban Nha. Một nghiên cứu quan sát có triển vọng

Bestetti RB, Dellalibera-Joviliano R, Lopes GS et al (2019) Determination of the Th1, Th2, Th17, and Treg cytokine profile in patients with chronic Chagas heart disease and systemic arterial hypertension. Heart Vessel 34:123–133. https://doi.org/10.1007/S00380-018-1228-Z Cardoso GM, Morato MJF, Gomes JAS et al (2006) Comparative analysis of cell phenotypes in different severe clinical forms of Chagas’ disease. Front Biosci 11:1158–1163. https://doi.org/10.2741/1870 Carrasco HA, Parada H, Guerrero L et al (1994) Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas’ disease. Int J Cardiol 43:27–38. https://doi.org/10.1016/0167-5273(94)90087-6 Cristovão-Silva AC, Brelaz-de-Castro MCA, Hernandes MZ, Pereira VRA (2021) Chagas disease: immunology of the disease at a glance. Cytokine Growth Factor Rev 62:15–22. https://doi.org/10.1016/J.CYTOGFR.2021.10.001 de Sousa RC, de Deus DB, da Costa TÁ et al (2019) Correlation between the cytokine profile and anticongestive medication in patients with chronic chagasic cardiopathy. Rev Soc Bras Med Trop 52. https://doi.org/10.1590/0037-8682-0386-2019 Ferreira RR, Waghabi MC, Bailly S et al (2022) The search for biomarkers and treatments in Chagas disease: insights from TGF-beta studies and immunogenetics. Front Cell Infect Microbiol 11:767576. https://doi.org/10.3389/FCIMB.2021.767576 Flórez O, Martín J, González CI (2012) Genetic variants in the chemokines and chemokine receptors in Chagas disease. Hum Immunol 73:852–858. https://doi.org/10.1016/J.HUMIMM.2012.04.005 Flórez O, Martín J, González Rugeles CI (2011) Interleukin 4, interleukin 4 receptor-α and interleukin 10 gene polymorphisms in Chagas disease. Parasite Immunol 33:506–511. https://doi.org/10.1111/J.1365-3024.2011.01314.X Galván IL, Pascual OM, Herrero-Martínez JM et al (2019) Does progressive introduction of benznidazole reduce the chance of adverse events in the treatment of Chagas disease? Am J Trop Med Hyg 100:1477–1481. https://doi.org/10.4269/AJTMH.18-0638 Gascón J, Albajar P, Cañas E et al (2008) Diagnosis, management and treatment of chronic Chagas’ heart disease in areas where Trypanosoma cruzi infection is not endemic. Enferm Infecc Microbiol Clin 26:99–106. https://doi.org/10.1157/13115545 Gomes JAS, Bahia-Oliveira LMG, Rocha MOC et al (2003) Evidence that development of severe cardiomyopathy in human Chagas’ disease is due to a Th1-specific immune response. Infect Immun 71:1185–1193. https://doi.org/10.1128/IAI.71.3.1185-1193.2003 González F, Villar S, D’Attilio L et al (2018) Dysregulated network of immune, endocrine and metabolic markers is associated to more severe human chronic chagas cardiomyopathy. Neuroimmunomodulation 25:119–128. https://doi.org/10.1159/000491699 Grijalva A, Gallo Vaulet L, Agüero RN et al (2022) Interleukin 10 polymorphisms as risk factors for progression to Chagas disease cardiomyopathy: a case-control study and meta-analysis. Front Immunol 13:946350. https://doi.org/10.3389/FIMMU.2022.946350 Llaguno M, Da Silva MV, Batista LR et al (2019) T-cell immunophenotyping and cytokine production analysis in patients with Chagas disease 4 years after benznidazole treatment. Infect Immun 87:e00103–e00119. https://doi.org/10.1128/IAI.00103-19 Llaguno M, De Resende Pertili LAR, Da Silva MV et al (2011) The relationship between heart rate variability and serum cytokines in chronic chagasic patients with persistent parasitemia. Pacing Clin Electrophysiol 34:724–735. https://doi.org/10.1111/J.1540-8159.2010.03025.X Llenas-García J, Wikman-Jorgensen P, Gil-Anguita C et al (2021) Chagas disease screening in pregnant Latin American women: adherence to a systematic screening protocol in a non-endemic country. PLoS Negl Trop Dis 15:e0009281. https://doi.org/10.1371/journal.pntd.0009281 López L, Arai K, Giménez E et al (2006) C-reactive protein and interleukin-6 serum levels increase as Chagas disease progresses towards cardiac failure. Rev Esp Cardiol 59:50–56. https://doi.org/10.1016/S1885-5857(06)60048-0 Moretti E, Basso B, Cervetta L et al (2002) Patterns of cytokines and soluble cellular receptors in the sera of children with acute chagas’ disease. Clin Diagn Lab Immunol 9:1324–1327. https://doi.org/10.1128/CDLI.9.6.1324-1327.2002 Navarrete MN, Gutiérrez-Gutiérrez B, De Arellano-Ramos R et al (2016) Low incidence of adverse effects using a progressive regimen of benznidazole in Chagas disease. Clin Infect Dis 62:1052. https://doi.org/10.1093/CID/CIW009 Parisi V, Petraglia L, D’Esposito V et al (2019) Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. Int J Cardiol 274:326–330. https://doi.org/10.1016/J.IJCARD.2018.06.106 Pérez-Molina JA, Molina I (2018) Chagas disease. Lancet 391:82–94. https://doi.org/10.1016/S0140-6736(17)31612-4 Pissetti CW, Correia D, Braga TT et al (2009) Association between the plasma levels of TNF-alpha, IFN-gamma, IL-10, nitric oxide and specific IgG isotypes in the clinical forms of chronic Chagas disease. Rev Soc Bras Med Trop 42:425–430. https://doi.org/10.1590/S0037-86822009000400013 Poveda C, Fresno M, Gironès N et al (2014) Cytokine profiling in Chagas disease: towards understanding the association with infecting Trypanosoma cruzi discrete typing units (a BENEFIT TRIAL sub-study). PLoS One 9:e91154. https://doi.org/10.1371/JOURNAL.PONE.0091154 Ramírez JC, Cura CI, Da Cruz MO et al (2015) Analytical validation of quantitative real-time PCR methods for quantification of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. J Mol Diagn 17:605–615. https://doi.org/10.1016/J.JMOLDX.2015.04.010 Rodrigues AB, da Gama Torres HO, Nunes M et al (2022) Biomakers in chronic Chagas cardiomyopathy. Microorganisms 10. https://doi.org/10.3390/MICROORGANISMS10081602 Salvador F, Sánchez-Montalvá A, Martínez-Gallo M et al (2020) Serum IL-10 levels and its relationship with parasitemia in chronic Chagas disease patients. Am J Trop Med Hyg 102:159–163. https://doi.org/10.4269/AJTMH.19-0550 Schmunis GA, Yadon ZE (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115:14–21. https://doi.org/10.1016/j.actatropica.2009.11.003 Silva WT, Costa HS, de Lima VP et al (2020) Plasma levels of soluble TNF receptors are associated with cardiac function in patients with Chagas heart disease. Int J Cardiol 316:101–103. https://doi.org/10.1016/J.IJCARD.2020.04.053 Sousa GR, Gomes JAS, Fares RCG et al (2014) Plasma cytokine expression is associated with cardiac morbidity in chagas disease. PLoS One 9:e87082. https://doi.org/10.1371/JOURNAL.PONE.0087082 Souza PEA, Rocha MOC, Rocha-Vieira E et al (2004) Monocytes from patients with indeterminate and cardiac forms of Chagas’ disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun 72:5283–5291. https://doi.org/10.1128/IAI.72.9.5283-5291.2004 Sunnemark D, Ulfgren AK, Örn A, Harris RA (1996) Cytokine production in hearts of Trypanosoma cruzi-infected CBA mice: do cytokine patterns in chronic stage reflect the establishment of myocardial pathology? Scand J Immunol 44:421–429. https://doi.org/10.1046/J.1365-3083.1996.D01-328.X Teixeira MM, Gazzinelli RT, Silva JS (2002) Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 18:262–265. https://doi.org/10.1016/S1471-4922(02)02283-3 Turner MD, Nedjai B, Hurst T, Pennington DJ (2014) Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta 1843:2563–2582. https://doi.org/10.1016/J.BBAMCR.2014.05.014 Vasconcelos RHT, Azevedo EAN, Diniz GTN et al (2015) Interleukin-10 and tumour necrosis factor-alpha serum levels in chronic Chagas disease patients. Parasite Immunol 37:376–379. https://doi.org/10.1111/PIM.12183 Volta BJ, Bustos PL, Cardoni RL et al (2016) Serum cytokines as biomarkers of early Trypanosoma cruzi infection by congenital exposure. J Immunol 196:4596–4602. https://doi.org/10.4049/JIMMUNOL.1502504 Volta BJ, Bustos PL, González C et al (2021) Circulating cytokine and chemokine profiles of Trypanosoma cruzi-infected women during pregnancy and its association with congenital transmission. J Infect Dis 224:1086–1095. https://doi.org/10.1093/INFDIS/JIAB057 Wang Y, Wessel N, Kohse F et al (2021) Measurement of multiple cytokines for discrimination and risk stratification in patients with Chagas’ disease and idiopathic dilated cardiomyopathy. PLoS Negl Trop Dis 15. https://doi.org/10.1371/JOURNAL.PNTD.0008906 Ward LS, Guariento ME, Fernandes GA, Maciel RM (1999) Serum cytokines in chronic Chagas’ disease. Rev Soc Bras Med Trop 32:285–289. https://doi.org/10.1590/S0037-86821999000300010 WHO (2015) Chagas disease in Latin America : an epidemiological update based on 2010 estimates = Maladie de Chagas en Amérique latine : le point épidémiologique basé sur les estimations de 2010. Wkly Epidemiol Rec 90:33–43